Successful IPO and Strong Capital Position
Completed an initial public offering on NASDAQ, raising $314 million in gross proceeds, positioning the company for future growth with a strong balance sheet.
Impressive Revenue and Growth Metrics
Achieved $83.5 million in Q3 2025 revenue, a 117% increase from Q3 2024, and a 51% increase in test growth with 163,000 tests. Annualized revenue run rate reached $334 million.
Strong Gross Margin Expansion
Achieved a gross margin of 70% in Q3 2025, a 17 percentage point increase from the previous year, driven by ASP growth and cost reductions.
Positive GAAP Operating Margin
Reported an 11.5% positive GAAP operating margin, with the expectation to maintain positive GAAP operating income moving forward.
Significant Growth in Oncology Segment
Oncology revenues grew by 664% to $8.7 million in Q3 2025 compared to the same period last year.
Key Partnerships and Publications
Finalized an exclusive agreement with Johnson & Johnson and published studies validating the company's technology in prenatal and oncology settings.